A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

What Was Tested

This registered phase 1 trial tested Eloralintide.

The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.

The study drug will be administered subcutaneously (SC) (under the skin).

For each participant, the study will last about 14 weeks, excluding screening.

It had three arms (groups): Eloralintide (Group 1) (experimental), Eloralintide (Groups 2 and 3) (experimental) and Eloralintide (Group 3) (experimental).

Eloralintide administered subcutaneously (SC) in a control group of participants with normal renal function.

Eloralintide administered SC in groups of participants with impaired renal function.

Eloralintide administered SC in a group of participants with end-stage renal disease (ESRD) on stable hemodialysis.

The registry classes the interventions as drug.

Who Took Part

The registry lists 28 planned participants were the target.

It was open to people of any sex aged from 18 years up to 85 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Have a body weight of 55 kilograms (kg) or more and a body mass index (BMI) within the range of 19.0 to 40.0 kilograms per square meter (kg/m²), inclusive. Have acceptable blood pressure and pulse rate.

The full record lists 7 inclusion and 5 exclusion criteria; among the exclusions: have a history of chronic liver disease, acute or chronic hepatitis, including a history of autoimmune hepatitis, any evidence for hepatic impairments; have a current, functioning organ transplant. nonfunctional renal allografts may be considered; are receiving continuous hd or peritoneal dialysis.

How the Study Was Run

The set-up was non-randomized, parallel-group and open-label.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Eloralintide study: the participants and staff both knew the treatment.

It started in 2026-02-24 with completion listed for 2026-10.

It ran at 2 sites in United States (2).

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): PK: Maximum Observed Drug Concentration (Cmax) of LY3841136 (time frame: Predose on Day 1 up to Day 71).

What This Means in Plain Language

Put simply, this is a phase 1, non-randomized trial of Eloralintide in 28 people.

Its size is small, so on its own it can only give an early look.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Eloralintide compound page, all human trials.